Advanced Biomed's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Advanced Biomed's ROA in the fourth quarter of 2026?
Advanced Biomed Inc. achieved a return on average assets (ROA) of 62.64 % in its fourth quarter of 2026, which is below Advanced Biomed's average return on assets, which stands at 63.32%.

ROA has improved compared to 49.78% in the third quarter of 2026, due to net income growth.

However, within the Healthcare sector Advanced Biomed Inc. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 56, from total ROA ranking in the third quarter of 2026 at 82.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	1.55 %	-9.18 %	-0.65 %	44.81 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	7	5	4	-3	-3
Return On Assets (TTM)	62.64 %	49.78 %	40.32 %	-31.05 %	-32.39 %
ADVB's Total Ranking	# 56	# 82	#	#	#
Total Assets (TTM) in million	14	11	7	11	14
Seq. Total Assets Change	30.85 %	44.29 %	-30.94 %	-22.11 %	17.02 %
Seq. Net Income Change	-	-	-	-	-

ADVB's 5 Years Annual ROA >> Back to ADVB Management Effectiveness >> Compare ADVB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 0

Return On Assets Statistics
High	Average	Low
76.09 %	63.32 %	53.63 %
(Jun 30 2026)		(Dec 31 2025)

Financial Statements
Advanced Biomed's Assets	$ 14 million	ADVB's Balance sheet
Advanced Biomed's Income	$ 1 million	Quarterly ADVB's Income Statement
ADVB's Income by Division		See ADVB's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2024) FY 2025	FY	FY	FY
Y / Y Total Assets Change	90.23 %	-	-	-	-
Total Assets in million	14	7	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	7	-3	0	0	0
Annual Return On Assets	47.57 %	-37.71 %	-	-	-

ADVB's 5 Years Annual ROA >> Back to ADVB Management Effectiveness >> Compare ADVB ROA to its Competitors

Comment on ADVB's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 47.57 % compared to prior year, due to annual net income growth of % to $6.68 million, while value of Advanced Biomed's overall assets grew just by 90.23 % to $14.04 million, compared to $14.04 a year before.

More Return On Assets Ratios
ADVB's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADVB's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADVB's Competitors
Subscribers only: Roa for Advanced Biomed's Suppliers
Subscribers only: Return On Assets for ADVB's Customers

You may also want to know
ADVB's Roi	ADVB's Inventory Turnover Ratio	ADVB's Growth Rates	ADVB's Dividend Comparisons
	ADVB's Profitability Ratios	ADVB's Asset Turnover Ratio	ADVB's Dividend Growth
ADVB's Roe	ADVB's Valuation Ratios	ADVB's Financial Strength Ratios	ADVB's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Kyntra Bio Inc	156.80 %
Vor Biopharma Inc	154.23 %
Glucotrack Inc	151.40 %
Capforce Inc	141.40 %
Protagenic Therapeutics Inc new	137.58 %
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Arbutus Biopharma Corp	82.34 %
Oncotelic Therapeutics Inc	81.75 %
Advanced Biomed Inc.	76.09 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Escalon Medical Corp	42.96 %
Sanuwave Health Inc	39.15 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %

Date modified: 2026-10-14T16:54:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.